Back

Latest Forum Topics / DISA    Last:0.001 --

Post Reply

Big Break thru for Equition Post Reply Rate topic
MichaelSchenker Master	29-Dec-2021 21:04        MichaelSchenker About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yes, I agree it is still early days, in fact I like it this way. Gradual up instead of spiking up. This way we can time our exit and re-entry with plenty of time to re-position. Looking at a 6-month package. Simple way to look at it. From 0.006, it it likely to go up or go down from here? Answer is clear. Unlikely it will go down further. As per previous sessions, even if 0.005 is done, it' s really not much. Very unlikely we are able to buy at 0.005 LowLow12      ( Date: 29-Dec-2021 20:19) Posted: Still early days Very similar to Aoxin Q&M kind of testing deal Keep fingers cross and see the BBs tear down the wall of 7 first 1) License given by moh 2) manufacturing start 3) orders taken local first 4) orders taken overseas Huge revenue increase after June 2022 Hence this is a buy and chuck one side and wait it grow to be a multi bagger play MichaelSchenker      ( Date: 29-Dec-2021 19:19) Posted: That' s the way it should be..... I like the way information was progressively and gradually released to us, the public shareholders. Anyway the story is still developing, and not too late to position ourselves nicely. Again, may I ask if anybody managed to Buy at 0.005 today or the past few sessions? I really doubt so as the volume done for 0.005 is really too small, too insignificant. Tomorrow you may need to queue for 0.006.   Best bet 0.007, which I think is still a good entry point. Remember, it is always the exit point that matters. I have bought several tranches at 0.003, 0.005, and 0.006.  Good Luck to all holders!!
Useful To Me  Not Useful To Me
luckyfa Elite	29-Dec-2021 20:26        luckyfa About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hope Good to see ~30s reach with good business development (😁 like today news)... Going longer term, hope seeing giving out dividends.... 👍 LowLow12      ( Date: 29-Dec-2021 18:53) Posted: Bro Luckyfa Oceanus hit highest I think is 77 So this one u think hit how high ? :) Half of 77 is excellent already luckyfa      ( Date: 29-Dec-2021 18:32) Posted: This is enormous... Will be holding mid-longer term.... Guess the price could be much much more.... 😅
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 20:19        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Still early days Very similar to Aoxin Q&M kind of testing deal Keep fingers cross and see the BBs tear down the wall of 7 first 1) License given by moh 2) manufacturing start 3) orders taken local first 4) orders taken overseas Huge revenue increase after June 2022 Hence this is a buy and chuck one side and wait it grow to be a multi bagger play MichaelSchenker      ( Date: 29-Dec-2021 19:19) Posted: That' s the way it should be..... I like the way information was progressively and gradually released to us, the public shareholders. Anyway the story is still developing, and not too late to position ourselves nicely. Again, may I ask if anybody managed to Buy at 0.005 today or the past few sessions? I really doubt so as the volume done for 0.005 is really too small, too insignificant. Tomorrow you may need to queue for 0.006.   Best bet 0.007, which I think is still a good entry point. Remember, it is always the exit point that matters. I have bought several tranches at 0.003, 0.005, and 0.006.  Good Luck to all holders!!! LowLow12      ( Date: 29-Dec-2021 18:07) Posted: DISA Limited (Company Registration No. 197501110N) (Incorporated in the Republic of Singapore) (?Company? and together with its subsidiaries, the ?Group?) APPOINTMENT OF DIRECTORS AND CHANGE IN SHARHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD. Further to the news release on the signing of licensing agreement between Digital Life Line Pte. Ltd. (?DLL?), National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) to commercialise new saliva-based COVID-19 antigen rapid test (?ART?) kits released on 8 December 2021, the board of directors (the ?Board?) of the Company wishes to announce the following: (1) Professor Soo Khee Chee, Dr. Guy Heathers and Mr. John Wong Weng Foo will be appointed as the directors of DLL (?DLL Directors?) with effect from 29 December 2021 Professor Soo, who is one of the inventors of the new saliva-based COVID-19 ART technology, studied medicine in the University of Singapore and graduated in 1975. He did his surgical training in Sydney and then had his fellowship training in surgical oncology and head and neck surgery in London and New York. He returned to Singapore General Hospital in 1988 and has been there since. In 1993, he became the Head of the Department of Surgery and held that position for 11 years. He was for a period the Chairman of the NUS Department of Surgery. In 1997, he became the Founding Director of the National Cancer Centre Singapore and recently retired from that position after 20 years. He was also the Senior Vice Dean of Duke NUS Medical School and now continues to hold the Benjamin Sheares Professorship in Academic Medicine. He has just started his own surgical practice in Farrer Park Hospital. In his career in Singapore spanning 30 years, he has trained numerous general surgeons, surgeons with interest in cancer surgery and head and neck surgery. In that period of time, he has the pleasure of seeing many of these specialties have become recognised as leading practitioners in their respective fields in Singapore and regionally. He has been recognised as the pioneer and leading cancer surgeon in the country. He introduced complex surgery like peritonectomies for previously inoperable cancers in the abdominal cavity and major intraabdominal tumours including removal of invaded major blood vessels. In the field of head and neck surgery, he is recognised to have performed the most of complex operations for cancers in this region. He is also recognised for removal of limb soft tissue tumours. He also introduced isolated limb perfusion for the management of intransit metastases for skin tumours attempting to salvage limbs which would otherwise require amputations. Professor Soo has won several national awards including Public Administration (Gold), National Outstanding Mentor and the President?s Science and Technology Award. He is currently the Inaugural Benjamin Shears Professor in Academic Medicine for Duke-Nus Medical School. Dr. Guy Heathers is currently the Vice President of Business Development at Hummingbird Bioscience as well as consultant to a number of Singapore biotech companies and former Director of Technology Development at the National Cancer Centre, Singapore and Director of SingHealth Intellectual Properties office. Previously, Guy held a number of positions in the bioscience field in different continents, including CBO at Cancer Therapeutics CRC Pty Ltd, Melbourne Australia CEO at Amaranth Medical Pte Ltd (Singapore), Gateway Capital Pty Ltd (Australia) and Biotech Research Ventures Pte Ltd (Singapore). Earlier in his career, he held positions of Chief Operating Officer, Cancer Research Ventures Ltd and Head of Business Development, Cancer Research 1 Campaign Technology Ltd. He started his business career with 7 years of drug discovery management at Hoffmann-La Roche in Nutley, NJ, USA, across a number of therapeutic areas. In addition to these roles, Guy has been instrumental in creating and developing over 20 biotech start-ups during his career, including Cyclacel (listed on NASDAQ), Kudos (bought by Astra Zeneca) and Enleofen (bought by Boehringer Ingelheim) as well as numerous multi-million dollar international licensing and collaboration deals in the biotechnology industry. Mr. John Wong was a General Partner at General Atlantic Partners, LLC, a worldwide private equity firm, and the Group Managing Director for Hong Leong Corporation. Previously, he was also the Chairman of TSH Corporation Limited, Vice Chairman of China Yuchai Ltd, Managing Director of IBM Singapore, Sri Lanka and Brunei, a Trustee of Singapore Management University, and a Director of the Singapore Institute of Management, Asia Dekor Holdings Limited, Asia Dekor Pte Ltd and Goodpack Limited. Mr. Wong holds an MBA from Brunel University (UK) and completed the Advanced Management Programme at the University of Hawaii. Following the abovementioned appointments, with effect from 29 December 2021, the composition of the Board of DLL shall be as follows: Dr. Soo Khee Chee, Chairman Dr. Guy Heathers Mr. John Wong Weng Foo Mr. Chng Weng Wah, Managing Director and CEO Mr. Han Yang Kwang (2) Change in Shareholding Percentage of DLL The Board wishes to announce that Disa Digital Safety Pte. Ltd. (?DiSa?), a wholly owned subsidiary of the Company, has transferred 5,500 shares, representing 11% of the total issued and paid-up capital of DLL, to DLL Directors, Professor Soo Khee Chee and Mr John Wong Weng Foo: Transferee Professor Soo Khee Chee John Wong Weng Foo No. of Shares Transferred 3,000 2,500 Subscription Price S$300.00 S$250.00 Shareholding (%) 6% 5% Following the above transfer, with effect from 29 December 2021, the composition of shareholders of DLL shall be as follows: Name of Shareholder DiSa Chng Weng Wah * Professor Soo Khee Chee John Wong Weng Foo Total No. of Shares Held 41,000 3,500 3,000 2,500 50,000 Shareholding (%) 82% 7% 6% 5% 100% * Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company. The above transfer is considered a non-discloseable transaction under Rule 1008 of the Catalist Rules. The value that the DLL Directors brings through their knowledge, insight and experiences is immensely important for the long term success of DLL?s business. 2 BY ORDER OF THE BOARD Chng Weng Wah Managing Director and Chief Executive Officer 29 December 2021 This announcement has been reviewed by the Company?s sponsor, SAC Capital Private Limited (?Sponsor?). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (?SGX-ST?) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited) Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542. Telephone number: +65 6232 3210 About Digital Life Line Pte. Ltd. DLL, a 82% owned subsidiary of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. Digital Life Line has signed tri-party licensing agreement with National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke- NUS Academic Medical Centre and the NUS. About DiSa Digital Safety Pte. Ltd. DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (?DiSa Asset Protection System?). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns. DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017. About DISA Limited DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at http://www.digital-safety.com. 3
Useful To Me  Not Useful To Me
mattohoh Elite	29-Dec-2021 19:48        mattohoh About Contact  Quote this Post!
x 0   x 0  Alert Admin	https://links.sgx.com/1.0.0/corporate-announcements/FQAJ9HYSD42RALZZ/8c75eff550058ec6cdc35e1ec3819f858aa30544702c4c8e7cbe4a5cf522e3d0 yunyancool      ( Date: 29-Dec-2021 19:45) Posted: May I know where i can find this announcement?
Useful To Me  Not Useful To Me
yunyancool Member	29-Dec-2021 19:45        yunyancool About Contact  Quote this Post!
x 0   x 0  Alert Admin	May I know where i can find this announcement?
Useful To Me  Not Useful To Me
MichaelSchenker Master	29-Dec-2021 19:19        MichaelSchenker About Contact  Quote this Post!
x 0   x 0  Alert Admin	That' s the way it should be..... I like the way information was progressively and gradually released to us, the public shareholders. Anyway the story is still developing, and not too late to position ourselves nicely. Again, may I ask if anybody managed to Buy at 0.005 today or the past few sessions? I really doubt so as the volume done for 0.005 is really too small, too insignificant. Tomorrow you may need to queue for 0.006.   Best bet 0.007, which I think is still a good entry point. Remember, it is always the exit point that matters. I have bought several tranches at 0.003, 0.005, and 0.006.  Good Luck to all holders!!! LowLow12      ( Date: 29-Dec-2021 18:07) Posted: DISA Limited (Company Registration No. 197501110N) (Incorporated in the Republic of Singapore) (?Company? and together with its subsidiaries, the ?Group?) APPOINTMENT OF DIRECTORS AND CHANGE IN SHARHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD. Further to the news release on the signing of licensing agreement between Digital Life Line Pte. Ltd. (?DLL?), National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) to commercialise new saliva-based COVID-19 antigen rapid test (?ART?) kits released on 8 December 2021, the board of directors (the ?Board?) of the Company wishes to announce the following: (1) Professor Soo Khee Chee, Dr. Guy Heathers and Mr. John Wong Weng Foo will be appointed as the directors of DLL (?DLL Directors?) with effect from 29 December 2021 Professor Soo, who is one of the inventors of the new saliva-based COVID-19 ART technology, studied medicine in the University of Singapore and graduated in 1975. He did his surgical training in Sydney and then had his fellowship training in surgical oncology and head and neck surgery in London and New York. He returned to Singapore General Hospital in 1988 and has been there since. In 1993, he became the Head of the Department of Surgery and held that position for 11 years. He was for a period the Chairman of the NUS Department of Surgery. In 1997, he became the Founding Director of the National Cancer Centre Singapore and recently retired from that position after 20 years. He was also the Senior Vice Dean of Duke NUS Medical School and now continues to hold the Benjamin Sheares Professorship in Academic Medicine. He has just started his own surgical practice in Farrer Park Hospital. In his career in Singapore spanning 30 years, he has trained numerous general surgeons, surgeons with interest in cancer surgery and head and neck surgery. In that period of time, he has the pleasure of seeing many of these specialties have become recognised as leading practitioners in their respective fields in Singapore and regionally. He has been recognised as the pioneer and leading cancer surgeon in the country. He introduced complex surgery like peritonectomies for previously inoperable cancers in the abdominal cavity and major intraabdominal tumours including removal of invaded major blood vessels. In the field of head and neck surgery, he is recognised to have performed the most of complex operations for cancers in this region. He is also recognised for removal of limb soft tissue tumours. He also introduced isolated limb perfusion for the management of intransit metastases for skin tumours attempting to salvage limbs which would otherwise require amputations. Professor Soo has won several national awards including Public Administration (Gold), National Outstanding Mentor and the President?s Science and Technology Award. He is currently the Inaugural Benjamin Shears Professor in Academic Medicine for Duke-Nus Medical School. Dr. Guy Heathers is currently the Vice President of Business Development at Hummingbird Bioscience as well as consultant to a number of Singapore biotech companies and former Director of Technology Development at the National Cancer Centre, Singapore and Director of SingHealth Intellectual Properties office. Previously, Guy held a number of positions in the bioscience field in different continents, including CBO at Cancer Therapeutics CRC Pty Ltd, Melbourne Australia CEO at Amaranth Medical Pte Ltd (Singapore), Gateway Capital Pty Ltd (Australia) and Biotech Research Ventures Pte Ltd (Singapore). Earlier in his career, he held positions of Chief Operating Officer, Cancer Research Ventures Ltd and Head of Business Development, Cancer Research 1 Campaign Technology Ltd. He started his business career with 7 years of drug discovery management at Hoffmann-La Roche in Nutley, NJ, USA, across a number of therapeutic areas. In addition to these roles, Guy has been instrumental in creating and developing over 20 biotech start-ups during his career, including Cyclacel (listed on NASDAQ), Kudos (bought by Astra Zeneca) and Enleofen (bought by Boehringer Ingelheim) as well as numerous multi-million dollar international licensing and collaboration deals in the biotechnology industry. Mr. John Wong was a General Partner at General Atlantic Partners, LLC, a worldwide private equity firm, and the Group Managing Director for Hong Leong Corporation. Previously, he was also the Chairman of TSH Corporation Limited, Vice Chairman of China Yuchai Ltd, Managing Director of IBM Singapore, Sri Lanka and Brunei, a Trustee of Singapore Management University, and a Director of the Singapore Institute of Management, Asia Dekor Holdings Limited, Asia Dekor Pte Ltd and Goodpack Limited. Mr. Wong holds an MBA from Brunel University (UK) and completed the Advanced Management Programme at the University of Hawaii. Following the abovementioned appointments, with effect from 29 December 2021, the composition of the Board of DLL shall be as follows: Dr. Soo Khee Chee, Chairman Dr. Guy Heathers Mr. John Wong Weng Foo Mr. Chng Weng Wah, Managing Director and CEO Mr. Han Yang Kwang (2) Change in Shareholding Percentage of DLL The Board wishes to announce that Disa Digital Safety Pte. Ltd. (?DiSa?), a wholly owned subsidiary of the Company, has transferred 5,500 shares, representing 11% of the total issued and paid-up capital of DLL, to DLL Directors, Professor Soo Khee Chee and Mr John Wong Weng Foo: Transferee Professor Soo Khee Chee John Wong Weng Foo No. of Shares Transferred 3,000 2,500 Subscription Price S$300.00 S$250.00 Shareholding (%) 6% 5% Following the above transfer, with effect from 29 December 2021, the composition of shareholders of DLL shall be as follows: Name of Shareholder DiSa Chng Weng Wah * Professor Soo Khee Chee John Wong Weng Foo Total No. of Shares Held 41,000 3,500 3,000 2,500 50,000 Shareholding (%) 82% 7% 6% 5% 100% * Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company. The above transfer is considered a non-discloseable transaction under Rule 1008 of the Catalist Rules. The value that the DLL Directors brings through their knowledge, insight and experiences is immensely important for the long term success of DLL?s business. 2 BY ORDER OF THE BOARD Chng Weng Wah Managing Director and Chief Executive Officer 29 December 2021 This announcement has been reviewed by the Company?s sponsor, SAC Capital Private Limited (?Sponsor?). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (?SGX-ST?) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited) Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542. Telephone number: +65 6232 3210 About Digital Life Line Pte. Ltd. DLL, a 82% owned subsidiary of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. Digital Life Line has signed tri-party licensing agreement with National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke- NUS Academic Medical Centre and the NUS. About DiSa Digital Safety Pte. Ltd. DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (?DiSa Asset Protection System?). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns. DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017. About DISA Limited DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at http://www.digital-safety.com. 3
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 18:53        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Bro Luckyfa Oceanus hit highest I think is 77 So this one u think hit how high ? :) Half of 77 is excellent already luckyfa      ( Date: 29-Dec-2021 18:32) Posted: This is enormous... Will be holding mid-longer term.... Guess the price could be much much more.... 😅 LowLow12      ( Date: 29-Dec-2021 18:18) Posted: They have already today split the shareholding Looks like 7 wall will be crush by BB soon Crush 7 and let?s look forward to above 10 A good cny
Useful To Me  Not Useful To Me
luckyfa Elite	29-Dec-2021 18:32        luckyfa About Contact  Quote this Post!
x 0   x 0  Alert Admin	This is enormous... Will be holding mid-longer term.... Guess the price could be much much more.... 😅 LowLow12      ( Date: 29-Dec-2021 18:18) Posted: They have already today split the shareholding Looks like 7 wall will be crush by BB soon Crush 7 and let?s look forward to above 10 A good cny luckyfa      ( Date: 29-Dec-2021 18:15) Posted: Really positive news.... Today just loadup another few hundreds lots, added another small small amount to my 'lorry'....Support the company... TO THE MOON... 🚀 🚀 🚀
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 18:18        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	They have already today split the shareholding Looks like 7 wall will be crush by BB soon Crush 7 and let?s look forward to above 10 A good cny luckyfa      ( Date: 29-Dec-2021 18:15) Posted: Really positive news.... Today just loadup another few hundreds lots, added another small small amount to my 'lorry'....Support the company... TO THE MOON... 🚀 🚀 🚀 LowLow12      ( Date: 29-Dec-2021 18:09) Posted: MOH License on the way Party time January
Useful To Me  Not Useful To Me
luckyfa Elite	29-Dec-2021 18:15        luckyfa About Contact  Quote this Post!
x 0   x 0  Alert Admin	Really positive news.... Today just loadup another few hundreds lots, added another small small amount to my 'lorry'....Support the company... TO THE MOON... 🚀 🚀 🚀 LowLow12      ( Date: 29-Dec-2021 18:09) Posted: MOH License on the way Party time January
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 18:09        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	MOH License on the way Party time January
Useful To Me  Not Useful To Me
luckyfa Elite	29-Dec-2021 18:08        luckyfa About Contact  Quote this Post!
x 0   x 0  Alert Admin	Looking really positive and great potential.... Checkout announcement..... 👍 🚀 🚀 🚀
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 18:07        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	DISA Limited (Company Registration No. 197501110N) (Incorporated in the Republic of Singapore) (?Company? and together with its subsidiaries, the ?Group?) APPOINTMENT OF DIRECTORS AND CHANGE IN SHARHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD. Further to the news release on the signing of licensing agreement between Digital Life Line Pte. Ltd. (?DLL?), National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) to commercialise new saliva-based COVID-19 antigen rapid test (?ART?) kits released on 8 December 2021, the board of directors (the ?Board?) of the Company wishes to announce the following: (1) Professor Soo Khee Chee, Dr. Guy Heathers and Mr. John Wong Weng Foo will be appointed as the directors of DLL (?DLL Directors?) with effect from 29 December 2021 Professor Soo, who is one of the inventors of the new saliva-based COVID-19 ART technology, studied medicine in the University of Singapore and graduated in 1975. He did his surgical training in Sydney and then had his fellowship training in surgical oncology and head and neck surgery in London and New York. He returned to Singapore General Hospital in 1988 and has been there since. In 1993, he became the Head of the Department of Surgery and held that position for 11 years. He was for a period the Chairman of the NUS Department of Surgery. In 1997, he became the Founding Director of the National Cancer Centre Singapore and recently retired from that position after 20 years. He was also the Senior Vice Dean of Duke NUS Medical School and now continues to hold the Benjamin Sheares Professorship in Academic Medicine. He has just started his own surgical practice in Farrer Park Hospital. In his career in Singapore spanning 30 years, he has trained numerous general surgeons, surgeons with interest in cancer surgery and head and neck surgery. In that period of time, he has the pleasure of seeing many of these specialties have become recognised as leading practitioners in their respective fields in Singapore and regionally. He has been recognised as the pioneer and leading cancer surgeon in the country. He introduced complex surgery like peritonectomies for previously inoperable cancers in the abdominal cavity and major intraabdominal tumours including removal of invaded major blood vessels. In the field of head and neck surgery, he is recognised to have performed the most of complex operations for cancers in this region. He is also recognised for removal of limb soft tissue tumours. He also introduced isolated limb perfusion for the management of intransit metastases for skin tumours attempting to salvage limbs which would otherwise require amputations. Professor Soo has won several national awards including Public Administration (Gold), National Outstanding Mentor and the President?s Science and Technology Award. He is currently the Inaugural Benjamin Shears Professor in Academic Medicine for Duke-Nus Medical School. Dr. Guy Heathers is currently the Vice President of Business Development at Hummingbird Bioscience as well as consultant to a number of Singapore biotech companies and former Director of Technology Development at the National Cancer Centre, Singapore and Director of SingHealth Intellectual Properties office. Previously, Guy held a number of positions in the bioscience field in different continents, including CBO at Cancer Therapeutics CRC Pty Ltd, Melbourne Australia CEO at Amaranth Medical Pte Ltd (Singapore), Gateway Capital Pty Ltd (Australia) and Biotech Research Ventures Pte Ltd (Singapore). Earlier in his career, he held positions of Chief Operating Officer, Cancer Research Ventures Ltd and Head of Business Development, Cancer Research 1 Campaign Technology Ltd. He started his business career with 7 years of drug discovery management at Hoffmann-La Roche in Nutley, NJ, USA, across a number of therapeutic areas. In addition to these roles, Guy has been instrumental in creating and developing over 20 biotech start-ups during his career, including Cyclacel (listed on NASDAQ), Kudos (bought by Astra Zeneca) and Enleofen (bought by Boehringer Ingelheim) as well as numerous multi-million dollar international licensing and collaboration deals in the biotechnology industry. Mr. John Wong was a General Partner at General Atlantic Partners, LLC, a worldwide private equity firm, and the Group Managing Director for Hong Leong Corporation. Previously, he was also the Chairman of TSH Corporation Limited, Vice Chairman of China Yuchai Ltd, Managing Director of IBM Singapore, Sri Lanka and Brunei, a Trustee of Singapore Management University, and a Director of the Singapore Institute of Management, Asia Dekor Holdings Limited, Asia Dekor Pte Ltd and Goodpack Limited. Mr. Wong holds an MBA from Brunel University (UK) and completed the Advanced Management Programme at the University of Hawaii. Following the abovementioned appointments, with effect from 29 December 2021, the composition of the Board of DLL shall be as follows: Dr. Soo Khee Chee, Chairman Dr. Guy Heathers Mr. John Wong Weng Foo Mr. Chng Weng Wah, Managing Director and CEO Mr. Han Yang Kwang (2) Change in Shareholding Percentage of DLL The Board wishes to announce that Disa Digital Safety Pte. Ltd. (?DiSa?), a wholly owned subsidiary of the Company, has transferred 5,500 shares, representing 11% of the total issued and paid-up capital of DLL, to DLL Directors, Professor Soo Khee Chee and Mr John Wong Weng Foo: Transferee Professor Soo Khee Chee John Wong Weng Foo No. of Shares Transferred 3,000 2,500 Subscription Price S$300.00 S$250.00 Shareholding (%) 6% 5% Following the above transfer, with effect from 29 December 2021, the composition of shareholders of DLL shall be as follows: Name of Shareholder DiSa Chng Weng Wah * Professor Soo Khee Chee John Wong Weng Foo Total No. of Shares Held 41,000 3,500 3,000 2,500 50,000 Shareholding (%) 82% 7% 6% 5% 100% * Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company. The above transfer is considered a non-discloseable transaction under Rule 1008 of the Catalist Rules. The value that the DLL Directors brings through their knowledge, insight and experiences is immensely important for the long term success of DLL?s business. 2 BY ORDER OF THE BOARD Chng Weng Wah Managing Director and Chief Executive Officer 29 December 2021 This announcement has been reviewed by the Company?s sponsor, SAC Capital Private Limited (?Sponsor?). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (?SGX-ST?) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited) Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542. Telephone number: +65 6232 3210 About Digital Life Line Pte. Ltd. DLL, a 82% owned subsidiary of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. Digital Life Line has signed tri-party licensing agreement with National University of Singapore (?NUS?) and Singapore Health Services Pte. Ltd. (?SingHealth?) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke- NUS Academic Medical Centre and the NUS. About DiSa Digital Safety Pte. Ltd. DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (?DiSa Asset Protection System?). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns. DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017. About DISA Limited DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at http://www.digital-safety.com. 3
Useful To Me  Not Useful To Me
LowLow12 Elite	29-Dec-2021 09:31        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Trigger point 7 They already parked there Just wait for it luckyfa      ( Date: 29-Dec-2021 09:10) Posted: 👍 buy hold... Imo.... BIG hands waiting..... LowLow12      ( Date: 28-Dec-2021 15:36) Posted: The Ministry of Health (MOH) on Sunday said that it expects a new wave of local cases " soon" given the higher transmissibility of the Omicron variant. " In the coming days and weeks, we should expect more community cases, and rapid doubling of cases. This is again a process we need to go through, in order to live with COVID-19," it added. This news even better for the saliva kit Just buy keep and hold and wait for multiple bagger
Useful To Me  Not Useful To Me
luckyfa Elite	29-Dec-2021 09:10        luckyfa About Contact  Quote this Post!
x 0   x 0  Alert Admin	👍 buy hold... Imo.... BIG hands waiting..... LowLow12      ( Date: 28-Dec-2021 15:36) Posted: The Ministry of Health (MOH) on Sunday said that it expects a new wave of local cases " soon" given the higher transmissibility of the Omicron variant. " In the coming days and weeks, we should expect more community cases, and rapid doubling of cases. This is again a process we need to go through, in order to live with COVID-19," it added. This news even better for the saliva kit Just buy keep and hold and wait for multiple bagger
Useful To Me  Not Useful To Me
LowLow12 Elite	28-Dec-2021 15:36        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	The Ministry of Health (MOH) on Sunday said that it expects a new wave of local cases " soon" given the higher transmissibility of the Omicron variant. " In the coming days and weeks, we should expect more community cases, and rapid doubling of cases. This is again a process we need to go through, in order to live with COVID-19," it added. This news even better for the saliva kit Just buy keep and hold and wait for multiple bagger
Useful To Me  Not Useful To Me
LowLow12 Elite	28-Dec-2021 15:34        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	You have to wait for MOH fast track approval lor with Omicron more and more transmissible and spreading around like hot cakes. The regulatory approval should be within January and then DISA can start manufacturing through their third party company. Should be the most sellable ART in the market No need poke the nose or ass That?s the plus point. Wait for BBs attack 7. Should be soon tankoksee      ( Date: 28-Dec-2021 14:42) Posted: DISA Unit to Commercialise New Saliva-Based COVID-19 Antigen Rapid Test Kits any updates?
Useful To Me  Not Useful To Me
tankoksee Supreme	28-Dec-2021 14:42        tankoksee About Contact  Quote this Post!
x 0   x 0  Alert Admin	DISA Unit to Commercialise New Saliva-Based COVID-19 Antigen Rapid Test Kits any updates?
Useful To Me  Not Useful To Me
mattohoh Elite	28-Dec-2021 13:19        mattohoh About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hopefully hehe. Those contra player which bought 0.005 and sold yesterday at 0.006 will try to buy for 0.005 again. Hopefully will see 0.006-0.007 soon
Useful To Me  Not Useful To Me
LowLow12 Elite	28-Dec-2021 11:59        LowLow12 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Maybe BB action afternoon Attacking 7. Huat Huat tankoksee      ( Date: 28-Dec-2021 11:11) Posted: hope the co can provide once a week or 2 weeks updates on their saliva testings progress.. LowLow12      ( Date: 28-Dec-2021 10:37) Posted: Next target will be to clear the 7 wall. Wait for BBs to eat all 6 and pad 6 buy wall thick thick
Useful To Me  Not Useful To Me

                                                         First   < Newer   881-900 of 2522   Older>   Last